
Atazanavir API is an antiretroviral medication that is primarily used in the treatment of HIV infection. It belongs to a class of drugs called protease inhibitors, which work by inhibiting the protease enzyme that HIV needs to replicate, thereby reducing the viral load in the body. It inhibits the action of the protease enzyme, which is crucial for the maturation of infectious virus particles. By preventing this process, the drug helps to suppress the viral replication, thereby controlling the infection.
Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.
COA
|
|
||
|
Product Name |
CAS Number |
Batch Number |
|
Atazanavir API |
198904-31-3 |
MB2606130521 |
|
Manufacturer Date |
Analysis Date |
Expiry Date |
|
2026/6/13 |
2026/6/15 |
2028/6/15 |
|
Sample Qty Base |
Packing |
Test Method |
|
1.5KGS |
25GS/bottle |
HPLC |
|
|
||
|
Item |
Standard |
Results |
|
Appearance |
White powder |
Complies |
|
Odor & Taste |
Characteristic |
Complies |
|
Identification - IR |
IR |
Complies |
|
Identification - HPLC |
HPLC |
Complies |
|
Loss on drying |
≤1.0% |
0.17% |
|
Residue on ignition |
≤0.1% |
0.03% |
|
Heavy metals |
≤20ppm |
Complies |
|
Impurity A |
≤0.1% |
Not detected |
|
Impurity B |
≤0.1% |
Not detected |
|
Impurity C |
≤0.1% |
0.02% |
|
Single impurity |
≤0.2% |
0.17% |
|
Total impurity |
≤1.0% |
0.60% |
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
|
|
||
Molecular Mechanisms
Competitive Binding and Protease Cleavage Inhibition
Transition-State Mimicry: The central hydroxyl group (-OH) of Atazanavir mimics the transition state during peptide bond cleavage, enabling tight competitive binding to the two catalytic aspartic acid residues (Asp25 / Asp25') in the HIV-1 protease homodimer active site.
Blockade of Gag / Gag-Pol Processing: By selectively inhibiting viral polyprotein processing, Atazanavir prevents capsid core condensation and virion maturation, producing non-infectious, morphologically immature viral particles.


Host Metabolic Enzymes and Transporter Interactions
UGT1A1 Enzyme Inhibition: Atazanavir is a potent inhibitor of human uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). It blocks the glucuronidation of unconjugated bilirubin, serving as the primary molecular driver for hyperbilirubinemia in clinical and preclinical safety studies.
CYP3A4 and P-gp Substrate/Inhibitor: It functions as both a substrate and a competitive inhibitor of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp / ABCB1), making it a key reference compound for investigating "pharmacokinetic boosting" phenomena and transmembrane transport kinetics.
Physicochemical Properties
Atazanavir solubility decreases as pH rises. Gastric acidity is therefore an important factor in oral absorption, and acid-reducing medicines can lower atazanavir exposure. This pH dependence should be considered throughout API selection, formulation development, and evaluation of drug interactions.
A single solubility result in purified water is insufficient to characterize its formulation behavior. More useful measurements include solubility and dissolution across relevant pH conditions, particle size, solid-state properties, and stability with the intended excipients. A change in salt form or particle size may improve dissolution under selected test conditions, but its effect on the finished product must be verified.

Metabolic Enzymes and Drug Interactions

Atazanavir is closely associated with CYP3A-mediated metabolism and inhibits UGT1A1. Interaction studies must consider both directions: a co-administered medicine may change atazanavir exposure, while atazanavir or its booster may change exposure to another medicine. Acid-reducing agents, CYP3A-related medicines, and other antiretrovirals are important groups to evaluate.
Resistance Research
Changes in the HIV-1 protease gene can reduce susceptibility to atazanavir. Resistance assessment should consider prior exposure to protease inhibitors, the viral protease genotype, phenotypic susceptibility when available, and the activity of the other medicines in the regimen. A single mutation should not be treated as a complete cross-resistance profile: combinations of mutations and treatment history affect interpretation.

FAQ
How should Atazanavir API powder and liquid stock solutions be stored?
Desiccated raw powder should be stored at -20°C away from light, while DMSO stock solutions should be aliquoted and frozen at -80°C to avoid freeze-thaw cycles.
What key resistance mutations are associated with Atazanavir in HIV-1 research?
The I50L mutation in the HIV-1 protease gene is the signature primary mutation conferring specific resistance to Atazanavir.
Why is Atazanavir frequently studied in combination with pharmacokinetic enhancers like Ritonavir or Cobicistat?
Because Atazanavir is extensively metabolized by CYP3A4, co-administering CYP3A inhibitors significantly boosts its intracellular and systemic drug levels.
What is the primary mechanism of action of Atazanavir in antiretroviral research?
Atazanavir is an azapeptide HIV-1 protease inhibitor that selectively blocks the Gag-Pol polyprotein cleavage, preventing immature virions from developing into infectious virus particles.
Hot Tags: atazanavir api, China atazanavir api manufacturers, suppliers, factory, cobicistat fine powder, heparin sodium pharmaceutical grade material, mirabegron compound powder, Omadacycline Powder, picamilon api, progesterone active pharmaceutical ingredient



